Asset
BITOPERTIN
Disc Medicine Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05883748 | phase2_3 | enrolling_by_invitation | 2023-08-31 | 2028-06-01 | Disc Medicine, Inc | HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP |
| NCT06910358 | phase3 | active_not_recruiting | 2025-04-04 | 2026-09-01 | Disc Medicine, Inc | Study of Bitopertin in Participants With EPP or XLP (APOLLO) |
| NCT05308472 | phase2 | completed | 2022-10-31 | 2024-02-20 | Disc Medicine, Inc | Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP |
FDA applications (0)
This company has no applications containing this asset.